Ischemia-modified albumin and adenosine plasma concentrations are associated with severe systemic inflammatory response syndrome after cardiopulmonary bypass

Journal of Critical Care

Volumn 28, Issue 5, 2013, Pages 747-755

  Nee, Laetitia ^a   Giorgi, Roch ^b   Garibaldi, Vlad ^b   Bruzzese, Laurie ^a   Blayac, Dorothée ^a   Fromonot, Julien ^b   Kipson, Nathalie ^a   Bellezza, Maurice ^a   Lejeune, Pierre Jean ^a,b   Guieu, Régis ^a,b   Kerbaul, François ^a  

^a TIMONE HOSPITAL   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

Author keywords

Adenosine; Ischemia modified albumin; SIRS

Indexed keywords

ADENOSINE; ADRENALIN; DOBUTAMINE; ISCHEMIA MODIFIED ALBUMIN; NORADRENALIN; VASOACTIVE AGENT;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; ARTIFICIAL VENTILATION; CARDIOPULMONARY BYPASS; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY OBSTRUCTION; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; HEART MUSCLE REVASCULARIZATION; HUMAN; INTENSIVE CARE UNIT; INTRAOPERATIVE PERIOD; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE PERIOD; PREDICTION; PREOPERATIVE PERIOD; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

ADENOSINE; ISCHEMIA-MODIFIED ALBUMIN; SIRS;

ADENOSINE; AGED; ALBUMINS; ANESTHESIA; BIOLOGICAL MARKERS; CARDIOPULMONARY BYPASS; CORONARY DISEASE; FEMALE; HEMODYNAMICS; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 84883554689     PISSN: 08839441     EISSN: 15578615     Source Type: Journal    
DOI: 10.1016/j.jcrc.2013.02.014     Document Type: Article

References (46)

1. Wan S., LeClerc J.L., Vincent J.L. Inflammatory response to cardiopulmonary bypass: mechanisms involved and possible therapeutic strategies. Chest 1997, 112:676-692.
2. Kerbaul F., Guidon C., Lejeune P.J., et al. Hyperprocalcitonemia is related to noninfectious postoperative severe systemic inflammatory response syndrome associated with cardiovascular dysfunction after coronary artery bypass graft surgery. J Cardiothorac Vasc Anesth 2002, 161:47-53.
3. Ménasché P. The inflammatory response to cardiopulmonary bypass and its impact on postoperative myocardial function. Curr Opin Cardiol 1995, 10:597-604.
4. Benoit M.O., Paris M., Silleran J., et al. Cardiac troponin I: its contribution to the diagnosis of perioperative myocardial infarction and various complications of cardiac surgery. Crit Care Med 2001, 2910:1880-1886.
5. Kerbaul F., Collart F., Bénard F., et al. Release of markers of myocardial damage evaluated in the coronary sinus during cardiac surgery. J Invest Med 2007, 55:195-201.
6. Lasocki S., Provenchère S., Bénessiano J., et al. Cardiac troponin I is an independent predictor of in-hospital death after adult cardiac surgery. Anesthesiology 2002, 97:405-411.
7. Bar-Or D., Rael L.T., Bar-Or R., Slone D.S., et al. The cobalt-albumin binding assay: insights into its mode of action. Clin Chim Acta 2008, 387:120-127.
8. Sinha M.K., Roy D., Gaze D.C., et al. Role of "ischemia modified albumin," a new biochemical marker of myocardial ischaemia, in the early diagnosis of acute coronary syndromes. Emerg Med J 2004, 21:29-34.
9. Peacock F., Morris D.L., Anwaruddin S., et al. Meta-analysis of ischemia-modified albumin to rule out acute coronary syndromes in the emergency department. Am Heart J 2006, 152:253-262.
10. Roy D., Quiles J., Sharma R., Sinha M. Ischemia-modified albumin concentrations in patients with peripheral vascular disease and exercise-induced skeletal muscle ischemia. Clin Chem 2004, 50:1656-1660.
11. Kerbaul F., Collart F., Giorgi R., et al. Role of endogenous adenosine as a predicitve marker of vasoplegia during CBP and postoperative severe systemic inflammatory response. Crit Care Med 2006, 34:640-645.
12. Kerbaul F., Bénard F., Giorgi R., et al. Adenosine A2A receptor hyperexpression in patients with severe SIRS after CBP. J Investig Med 2008, 56:864-871.
13. Hack B., Witting P.K., Rayner B.S., et al. Oxidant stress and damage in post-ischemic mouse hearts: effects of adenosine. Mol Cell Biochem 2006, 287:165-175.
14. Sollevi A. Cardiovascular effects of adenosine in man; possible clinical implications. Prog Neurobiol 1986, 27:319-349.
15. Paganelli F., Saadjian A., Sampol J.J., et al. Effects of percutaneous transluminal coronary angioplasty on coronary adenosine concentrations in humans. Eur J Clin Invest 2000, 30:105-109.
16. Universal definition of myocardial infarction expert consensus document. Eur Heart J 2007, 28:2525-2538.
17. Provenchère S., Plantefève G., Hufnagel G., et al. Renal dysfunction after cardiac surgery with normothermic cardiopulmonary bypass: incidence, risk factors, and effect on clinical outcome. Anesth Analg 2003, 96:1258-1264.
18. Muckart D.J.J., Bhagwanjee S. American College of Chest Physicians/Society of Critical Care Medicine consensus conference definitions of the systemic inflammatory response syndrome and allied disorders in relation to critically injured patients. Crit Care Med 1997, 25:1789-1795.
19. Fagon J.Y., Chastre A., Novara P., et al. Characterization of intensive care unit patients using a model based on the presence or absence of organ dysfunctions and/or infection: the ODIN model. Intensive Care Med 1993, 19:137-144.
20. Nashef S.A.M., Roques F., Michel P., et al. European System for Cardiac Operative Risk Evaluation (EuroSCORE). Eur J Cardiothorac Surg 1999, 16:9-13. The Euro SCORE study group.
21. Guieu R., Paganelli F., Sampieri F., et al. The use of HPLC to evaluate the variations of blood coronary adenosine concentrations during percutaneous transluminal angioplasty. Clin Chim Acta 1994, 230:63-68.
22. Guieu R., Sampieri F., Bechis G., et al. Developement of an HPLC/diode array detector method for the determination of human plasma adenosine concentrations. J Liq Chromatogr 1999, 22:1829-1841.
23. Saadjian A.Y., Paganelli F., Juin M., et al. Plasma beta-endorphin and adenosine concentration in pulmonary hypertension. Am J Cardiol 2000, 85:858-863.
24. Carrega L., Giaime P., Montserrat C., et al. Influence of the dialysis membrane on markers of tissue ischemia. J Investig Med 2006, 54:62-66.
25. DeLong E.R., DeLong D.M., Clarke-Pearson D.L. Comparing the areas under two or more correlated receiver operating characteristics curves: a nonparametric approach. Biometrics 1988, 44:837-845.
26. R Development Core Team A Language and Environment for Statistical Computing. R Foundation for Statistical Computing 2009.
27. Cremer J., Martin M., Redl H., et al. Systemic inflammatory response syndrome after cardiac operations. Ann Thorac Surg 1996, 61:1714-1720.
28. Etievent J.P., Chocron S., Toubin G., et al. Use of cardiac troponin I as a marker of perioperative myocardial ischaemia. Ann Thorac Surg 1995, 59:1192-1194.
29. Vermes E., Mesguich M., Houel R., Houel R., et al. Cardiac troponin I release after open heart surgery: a marker of myocardial protection?. Ann Thorac Surg 2000, 70:2087-2090.
30. Hennein H.A., Ebba H., Rodriguez J.L., et al. Relationship of the proinflammatory cytokines to myocardial ischemia and dysfunction after uncomplicated coronary revascularization. J Thorac Cardiovasc Surg 1994, 108:626-635.
31. Finkel M.S., Hoffman R.A., Shen L., et al. Interleukin 6 (IL6) as a mediator of stunned myocardium. Am J Cardiol 1993, 71:1231-1232.
32. Abboud H., Labreuche J., Meseguer E., et al. Ischaemia-modified albumin in acute stroke. Cerebrovasc Dis 2007, 23:216-220.
33. Gunduz A, Turedi S, Mentese A et al. Ischaemia-modified albumin concentration in cerebrovascular accidents. Am J Emerg Med 2008; 26:874-8.
34. Turedi S., Gunduz A., Mentese A., et al. Values of ischaemia-modified albumin in the diagnosis of pulmonar embolism. Am J Emerg Med 2007, 25:770-773.
35. Bar-Or D., Rael L.T., Bar-Or R., Slone D.S., et al. The cobalt albumin binding assay: insight into its mode of action. Clin Chim Acta 2008, 387:120-127.
36. Pellegrino P., Mallet B., Delliaux S., et al. Zeolites are effective ROS scavenger in vitro. Biochem Biophys Res Commun 2011, 410:478-483.
37. Sinha M.K., Roy D., Gaze D.C., et al. Role of ischaemai-modified albumin, a new biochemical marker of myocardial ischaemai in the early diagnosis of acute coronary syndromes. Emerg Med J 2004, 21:29-34.
38. Roy D., Quiles J., Aldama G., et al. Ischaemia modified albumin for the assesment of patients presenting to the emergency department with acute chest pain but normal or non-diagnostic 12 lead electrocardiograms and negative cardiac troponin T. Int J Cardiol 2004, 97:297-301.
39. Kanko M., Yavuz S., Duman C., et al. Ischaemia modified albumin as a prognostic factor in coronary bypass surgery. J Cardiothoracic Surgery 2012, 7:3.
40. Newholmes E.A., Leeche A.R. Pathways for the degradation of purines and pyrimidine nucleotides. Biochemistry for the medical Sciences 1992, 507-508. John Wiley & Sons, New York. 5th ed. Chichester (Ed.).
41. Ralevic V., Burnstock G. Receptors for purines and pyrimidines. Pharmacol Rev 1998, 50:413-492.
42. Fredholm B.B., Arslan G., Halldner L., et al. Structure and function of adenosine receptors and their genes. Arch Pharmacol 2000, 362:364-374.
43. Mosqueda-Garcia R., Tseng C.J., et al. Modulatory effects of adenosine on baroreflex activation in the brainstem of nomotensive rats. Eur J Pharmacol 1989, 174:119-122.
44. Cronstein B.N., Kubersky S.M., Weissmann G., Hirschhorn R. Activation of adenosine receptors inhibits hydrogen peroxide release by activated human neutrophils. Clin Immunol Immunopathol 1987, 42:76-85.
45. Martin C., Leone M., Viviand X., et al. High adenosine plasma concentration as a prognostic index for outcome in patients with septic shock. Crit Care Med 2000, 28:3198-3202.
46. Nemeth Z.H., Csoka B., Wilmanski J., et al. Adenosine A2 receptor inactivation increases survival in polymicrobial sepsis. J Immunol 2006, 176:5616-5626.